Melanocortin Receptor Obesity Program
Palatin Technologies has an exclusive global licensing and research collaboration agreement with AstraZeneca AB, a major international pharmaceutical and healthcare business, to discover, develop and commercialize compounds that target melanocortin-4 receptors for the treatment of obesity, diabetes and related metabolic syndrome.
The collaboration, based on Palatin’s melanocortin-4 receptor program for the treatment of obesity, provides AstraZeneca access to compound libraries, core technologies and expertise in melanocortin receptor drug discovery and development.
Palatin Technologies and AstraZeneca have made significant progress under the collaboration agreement, using core technologies in lead generation and expertise in melanocortin biology developed by Palatin Technologies. A near term objective of the collaboration with AstraZeneca is to advance a commercial drug candidate into clinical trials.
For more information on Palatin’s Melanocortin Receptor Obesity Program, download the fact sheet.
|
